Skip to content

An evaluation on the short-term efficacy and safety of 0.01% compound betamethasone mouth rinse in treatment of oral erosion lichen planus: a randomized controlled clinical trial

An evaluation on the short-term efficacy and safety of 0.01% compound betamethasone mouth rinse in treatment of oral erosion lichen planus: a randomized controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016507
Enrollment
Unknown
Registered
2018-06-05
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral lichen planus

Interventions

Group A:0.01% compound betamethasone mouth rinse
Group B:0.02% dexamethasone mouth rinse

Sponsors

West China Hospital of Stomatology, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. OLP patients aged 18-60 years old; 2. Acute extensive or multi-focal erosion and the lesion size exceeding 1 square centimeter; 3. Disease-process exceeding 2 months; 4. Result of a physical examination is normal; 5. Negative reaction to pregnancy test in women; 6. Subject decided independently to participate in the study ,get rid of bad habits and follow the doctor's advice.

Exclusion criteria

Exclusion criteria: 1. Those with severe systemic diseases that can not control by medicine; 2. History of allergies to glucocorticoids; 3. Those taking immunotherapy during the previous 3 months; those having topical treatment of lichen planus within a week 4. Lichenoid disease induced by amalgam or other drugs; 5. Those with other severe mucous diseases; 6. Intention of pregnancy or lactation; 7. Using of contraceptives of steroid hormone recently; 8. Those with history of psychiatric disorders who can not to cooperate .

Design outcomes

Primary

MeasureTime frame
lesion size;pain level;plasma concentration;

Secondary

MeasureTime frame
healing rate;recurrence rate;

Countries

China

Contacts

Public ContactHongmei Zhou
acomnet@126.com+86 28 85503480

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026